Evaluation of antibody response after COVID?19 vaccination of healthcare workers

Basit Öğe Kaydı
dc.contributor.authorUysal, Elif B.
dc.contributor.authorGümüş, Sibel
dc.contributor.authorBektöre, Bayhan
dc.contributor.authorBozkurt, Hale
dc.contributor.authorGözalan, Ayşegül
dc.date.accessioned2024-10-24T10:44:35Z
dc.date.available2024-10-24T10:44:35Z
dc.date.issued2022
dc.departmentALKÜ, Fakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü
dc.description.abstractThe common goal of all vaccines developed against COVID-19, although they have been designed with different methods, is to develop an effective immunity and antibody response against SARS-CoV-2. However, the postvaccination immune response and antibody levels differ between individuals. This study examined the relationship between postvaccine seropositivity rates, age, gender, smoking, and body mass index (BMI), and antibody titers. A total of 314 healthcare workers (HCW) who were not previously infected with COVID-19 and who had received two doses of CoronaVac inactivated vaccine participated in the study. Seropositivity against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein was measured from the participants 4 weeks after the second dose of vaccine using the electrochemiluminescence (ECLIA) method. In addition, the antibody developed against the nucleocapsid protein (NCP) was evaluated and compared using Elecsys Anti-SARS-CoV-2 kit. One hundred and eighty-one of the participants were female (57.6%) with a median age of 39 (interquartile range [IQR], 10) and 133 (42.4%) were male with a median age of 41 (IQR, 11). 99.6% of the volunteers developed seropositivity 4 weeks after the second dose of vaccine. It was also observed that the rate of RBD protein antibody titer was >250 U/ml in smokers, which is quite low compared to nonsmokers (p = 0.032), and that high RBD antibody titers were proportionally lower in obese participants, according to BMI values, compared to those with normal BMI (49.5% and 9.9%). It was observed that seropositivity developed in almost all participants after the CoronaVac vaccine. However, it was determined that the antibody titer measured varied depending on factors such as smoking, BMI, and duration.
dc.identifier.doi10.1002/jmv.27420
dc.identifier.endpage1066en_US
dc.identifier.issue3en_US
dc.identifier.startpage1060en_US
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/34704620/
dc.identifier.urihttps://hdl.handle.net/20.500.12868/2508
dc.identifier.volume94en_US
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.relation.ispartofJournal of Medical Virology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCoronaVac
dc.subjectHealthcare workers
dc.subjectReceptor binding domain
dc.subjectSeropositivity
dc.subjectSpike protein
dc.titleEvaluation of antibody response after COVID?19 vaccination of healthcare workers
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
JMV-94-1060.pdf
Boyut:
694.36 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin // Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu